DE69820885D1 - Peptidsequenzen als scharnierregionen in proteinen wie immunglobulinfragmenten und ihre verwendung in der heilkunde - Google Patents

Peptidsequenzen als scharnierregionen in proteinen wie immunglobulinfragmenten und ihre verwendung in der heilkunde

Info

Publication number
DE69820885D1
DE69820885D1 DE69820885T DE69820885T DE69820885D1 DE 69820885 D1 DE69820885 D1 DE 69820885D1 DE 69820885 T DE69820885 T DE 69820885T DE 69820885 T DE69820885 T DE 69820885T DE 69820885 D1 DE69820885 D1 DE 69820885D1
Authority
DE
Germany
Prior art keywords
proteins
hinge regions
immunglobulin
healing
customers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69820885T
Other languages
English (en)
Other versions
DE69820885T2 (de
Inventor
Paul Humphreys
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Celltech Ltd
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Application granted granted Critical
Publication of DE69820885D1 publication Critical patent/DE69820885D1/de
Publication of DE69820885T2 publication Critical patent/DE69820885T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69820885T 1997-09-19 1998-09-21 Peptidsquenzen als Gelenkregionen in Proteinen wie Immunglobulinfragmenten und ihre Verwendung in der Medizin Expired - Fee Related DE69820885T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9720054.7A GB9720054D0 (en) 1997-09-19 1997-09-19 Biological products
GB9720054 1997-09-19
PCT/GB1998/002851 WO1999015549A2 (en) 1997-09-19 1998-09-21 Peptide sequences as hinge regions in proteins like immunoglobulin fragments and their use in medicine

Publications (2)

Publication Number Publication Date
DE69820885D1 true DE69820885D1 (de) 2004-02-05
DE69820885T2 DE69820885T2 (de) 2004-12-16

Family

ID=10819407

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69820885T Expired - Fee Related DE69820885T2 (de) 1997-09-19 1998-09-21 Peptidsquenzen als Gelenkregionen in Proteinen wie Immunglobulinfragmenten und ihre Verwendung in der Medizin

Country Status (9)

Country Link
US (1) US6642356B1 (de)
EP (1) EP1015495B1 (de)
JP (1) JP4257030B2 (de)
AT (1) ATE257160T1 (de)
AU (1) AU9174398A (de)
DE (1) DE69820885T2 (de)
ES (1) ES2212340T3 (de)
GB (1) GB9720054D0 (de)
WO (1) WO1999015549A2 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
ATE384783T1 (de) * 2001-10-19 2008-02-15 Zymogenetics Inc Dimerisierter wachstumsfaktor sowie materialien und verfahren zu seiner herstellung
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
US20050163782A1 (en) * 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
EP1983000B1 (de) 2003-11-21 2015-09-02 UCB Biopharma SPRL Verfahren zur Behandlung von multipler Sklerose mittels Hemmung der IL-17-Aktivität
ATE517914T1 (de) * 2004-03-08 2011-08-15 Zymogenetics Inc Dimere fusionsproteine und materialien und verfahren zu deren herstellung
ES2408704T3 (es) 2005-01-05 2013-06-21 Biogen Idec Ma Inc. Moléculas de unión a Cripto
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
JP5255435B2 (ja) 2005-04-26 2013-08-07 メディミューン，エルエルシー ヒンジドメイン操作による抗体エフェクター機能の調節
ES2382879T3 (es) 2005-09-14 2012-06-14 Ucb Pharma, S.A. Conjugado de anticuerpo - polímero de peine.
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
GEP20146112B (en) 2007-03-22 2014-06-25 Ucb Pharma Sa Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and usage thereof
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
ES2622460T3 (es) 2007-09-26 2017-07-06 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
ES2667258T3 (es) 2009-09-10 2018-05-10 Ucb Biopharma Sprl Anticuerpos multivalentes
GB0916630D0 (en) 2009-09-22 2009-11-04 Secr Defence Antibody
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
EP2550297B1 (de) 2010-03-25 2019-01-23 UCB Biopharma SPRL Mit disulfid stabilisierte dvd-lg-moleküle
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
EP2565667A1 (de) 2011-08-31 2013-03-06 Friedrich-Alexander-Universität Erlangen-Nürnberg Ankunftsrichtungsschätzung mittels mit einem Wasserzeichen versehenen Audiosignalen und Mikrofonanordnungen
US20140234903A1 (en) 2011-09-05 2014-08-21 Eth Zurich Biosynthetic gene cluster for the production of peptide/protein analogues
WO2013068571A1 (en) 2011-11-11 2013-05-16 Ucb Pharma S.A. Albumin binding antibodies and binding fragments thereof
EP2880057A4 (de) * 2012-08-02 2016-03-23 Jn Biosciences Llc Durch cysteinmutation und ein mu-endstück multimerisierte antikörper oder fusionsproteine
CA2939198A1 (en) 2014-03-05 2015-09-11 Ucb Biopharma Sprl Multimeric fc proteins
US10316097B2 (en) 2015-05-27 2019-06-11 Ucb Biopharma Sprl Method for the treatment of epilepsy, epileptogenesis, seizures or convulsions by an anti-colony-stimulating factor 1 receptor (CSF-1R) antibody
EP4137158A1 (de) 2015-08-07 2023-02-22 Imaginab, Inc. Gegen moleküle gerichtete antigenbindende konstrukte
US20180271998A1 (en) 2015-12-04 2018-09-27 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
AU2018382586A1 (en) 2017-12-14 2020-07-02 CSL Behring Lengnau AG Recombinant igG Fc multimers for the treatment of neuromyelitis optica
GB201804243D0 (en) * 2018-03-16 2018-05-02 Liverpool School Tropical Medicine Hinge sequences
JP7398396B2 (ja) 2018-06-01 2023-12-14 ノバルティス アーゲー Ｂｃｍａに対する結合分子及びその使用
CN114173810A (zh) 2019-05-21 2022-03-11 诺华股份有限公司 针对bcma的三特异性结合分子及其用途
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
AU2020279974A1 (en) 2019-05-21 2021-11-18 Novartis Ag CD19 binding molecules and uses thereof
JP2022543669A (ja) 2019-08-08 2022-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 新規抗原結合分子フォーマット
BR112022003713A2 (pt) 2019-09-13 2022-08-09 CSL Behring Lengnau AG Multímeros de fc de igg recombinantes para o tratamento de doenças renais mediadas por imunocomplexo
US20210130477A1 (en) 2019-11-05 2021-05-06 Regeneron Pharmaceuticals, Inc. N-TERMINAL scFv MULTISPECIFIC BINDING MOLECULES
CA3164731A1 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
CN116249549A (zh) 2020-03-27 2023-06-09 诺华股份有限公司 用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
JP2023525555A (ja) 2020-05-12 2023-06-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 新規なｉｌ１０アゴニストおよびその使用方法
EP4228693A1 (de) 2020-10-13 2023-08-23 Janssen Biotech, Inc. Biotechnologisch hergestellte t-zell-vermittelte immunität, materialien und andere verfahren zur modulation eines clusters der differenzierung iv und/oder viii
IL302412A (en) 2020-11-06 2023-06-01 Novartis Ag Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
EP4240491A1 (de) 2020-11-06 2023-09-13 Novartis AG Cd19-bindende moleküle und verwendungen davon
JP2024517844A (ja) 2021-05-04 2024-04-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 多重特異性ｆｇｆ２１受容体アゴニスト及びそれらの使用
CA3226924A1 (en) 2021-07-19 2023-01-26 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
WO2023022965A2 (en) 2021-08-16 2023-02-23 Regeneron Pharmaceuticals, Inc. Novel il27 receptor agonists and methods of use thereof
US20230279153A1 (en) 2021-11-11 2023-09-07 Regeneron Pharmaceuticals, Inc. Cd20-pd1 binding molecules and methods of use thereof
WO2023220647A1 (en) 2022-05-11 2023-11-16 Regeneron Pharmaceuticals, Inc. Multispecific binding molecule proproteins and uses thereof
US20230382969A1 (en) 2022-05-27 2023-11-30 Regeneron Pharmaceuticals, Inc. Interleukin-2 proproteins and uses thereof
US20230391844A1 (en) 2022-06-04 2023-12-07 Regeneron Pharmaceuticals, Inc. Interleukin-2 proproteins and uses thereof
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
WO2024040247A1 (en) 2022-08-18 2024-02-22 Regeneron Pharmaceuticals, Inc. Interferon proproteins and uses thereof
WO2024130175A2 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Antigen-binding molecules that bind to aav particles and uses
WO2024138191A1 (en) 2022-12-23 2024-06-27 Regeneron Pharmaceuticals, Inc. Ace2 fusion proteins and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284898A3 (de) 1987-04-02 1990-06-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Hinge-Peptid, Verfahren zu seiner Herstellung und seine Verwendung zur Herstellung synthetischer Immunogene
ATE225801T1 (de) * 1992-07-13 2002-10-15 Bionebraska Inc Verfahren zur modifizierung rekombinanter polypeptide

Also Published As

Publication number Publication date
JP4257030B2 (ja) 2009-04-22
ATE257160T1 (de) 2004-01-15
AU9174398A (en) 1999-04-12
EP1015495A2 (de) 2000-07-05
EP1015495B1 (de) 2004-01-02
JP2001517423A (ja) 2001-10-09
WO1999015549A2 (en) 1999-04-01
WO1999015549A3 (en) 1999-06-17
GB9720054D0 (en) 1997-11-19
DE69820885T2 (de) 2004-12-16
ES2212340T3 (es) 2004-07-16
US6642356B1 (en) 2003-11-04

Similar Documents

Publication Publication Date Title
DE69820885D1 (de) Peptidsequenzen als scharnierregionen in proteinen wie immunglobulinfragmenten und ihre verwendung in der heilkunde
Selsted et al. Determination of the disulfide array in the human defensin HNP-2: a covalently cyclized peptide
Aggarwal et al. Human tumor necrosis factor. Production, purification, and characterization.
Mann et al. Solubilization of protein BM‐40 from a basement membrane tumor with cheating agents and evidence for its identity with osteonectin and SPARC
Hackeng et al. Total chemical synthesis of human matrix Gla protein
Skorstengaard et al. Complete primary structure of the collagen‐binding domain of bovine fibronectin
AU4162400A (en) Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii
NO964650D0 (no) LAG-3 protein-opplöselige polypeptidfraksjoner, fremgangsmåte for fremstilling, teraupeutisk preparat og anti-idiotype antistoff
ATE477272T1 (de) Verwendung von stefin a als gerüstprotein
AU1207301A (en) Stabilized proteins
DK1025237T3 (da) Human kontrolpunktskinase, hCDS1, præparater og fremgangsmåder
WO2001005810A3 (de) CYCLISCHE PEPTIDDERIVATE ALS INHIBITOREN DES INTEGRINS αvβ¿6?
DE69926627D1 (de) Insulinartigen wachstumsfaktor bindendes protein -3 variante
DE68917837D1 (de) Peptid-Verbindungen.
DE59712235D1 (de) Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe
Araki et al. The position of the disulfide bonds in human plasma α2HS-glycoprotein and the repeating double disulfide bonds in the domain structure
Garcia-Pardo et al. Primary structure of human plasma fibronectin—characterization of the 6,000 dalton C-terminal fragment containing the interchain disulfide bridges
WO1999002708A8 (en) Fusion proteins comprising sequences derived from bovine if1 atpase inhibitor protein
Le-Nguyen et al. Design and chemical synthesis of a 32 residues chimeric microprotein inhibiting both trypsin and carboxypeptidase A
WO2000049038A3 (de) Synthetische peptide des regulatorischen virusproteins r (vpr) des humanen immundefizienzvirus typ 1 (hiv-1) und ihre verwendung
WO1999031229A3 (en) Peptides and nucleic acids derived from eisenia foetida and the use thereof
IL150045A0 (en) Compositions and methods for detecting stress-inducible proteins
DE60038667D1 (de) De peptide und ihre verwendung
Ötvös et al. Coupling difficulty following replacement of Tyr with HOTic during synthesis of an analog of an EGF B‐loop fragment
TH62241A (th) ไบคูนินของคน

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee